Forte Biosciences Stock Today
| FBRX Stock | USD 15.60 0.20 1.27% |
Performance13 of 100
| Odds Of DistressLess than 18
|
Forte Biosciences is trading at 15.60 as of the 18th of January 2025; that is 1.27 percent decrease since the beginning of the trading day. The stock's open price was 15.8. Forte Biosciences has less than a 18 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of April 2017 | Category Healthcare | Classification Health Care |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. Forte Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.39 M outstanding shares of which 342.85 K shares are currently shorted by private and institutional investors with about 0.09 trading days to cover. More on Forte Biosciences
Moving together with Forte Stock
Moving against Forte Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Forte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Paul Wagner | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsForte Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Forte Biosciences' financial leverage. It provides some insight into what part of Forte Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Forte Biosciences (FBRX) is traded on NASDAQ Exchange in USA. It is located in 3060 Pegasus Park Drive, Dallas, TX, United States, 75247 and employs 11 people. Forte Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.74 M. Forte Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.39 M outstanding shares of which 342.85 K shares are currently shorted by private and institutional investors with about 0.09 trading days to cover.
Forte Biosciences currently holds about 38.55 M in cash with (28.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.89.
Check Forte Biosciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Forte Biosciences is $99.74 Million. Over half of Forte Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Forte Ownership Details
Forte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adar1 Capital Management Llc | 2024-09-30 | 6 K | |
| Ubs Group Ag | 2024-09-30 | 1.6 K | |
| Tower Research Capital Llc | 2024-09-30 | 806 | |
| Group One Trading, Lp | 2024-09-30 | 559 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 151 | |
| Royal Bank Of Canada | 2024-06-30 | 137 | |
| Bank Of America Corp | 2024-09-30 | 23.0 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 20.0 | |
| Acadian Asset Management Llc | 2024-09-30 | 18.0 | |
| Tybourne Capital Management (hk) Ltd | 2024-09-30 | 145 K | |
| Bvf Inc | 2024-09-30 | 119.3 K |
Forte Biosciences Historical Income Statement
Forte Stock Against Markets
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.